Ono Pharmaceutical Co Ltd
TSE:4528
Intrinsic Value
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. [ Read More ]
The intrinsic value of one
Ono Pharmaceutical Co Ltd
stock under the Base Case scenario is
4 552.2
JPY.
Compared to the current market price of 2 290.5 JPY,
Ono Pharmaceutical Co Ltd
is
Undervalued by 50%.
Ono Pharmaceutical Co Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Ono Pharmaceutical Co Ltd's market capitalization is 1.1T JPY.
Ono Pharmaceutical Co Ltd stock price is 2 290.5 JPY.
Ono Pharmaceutical Co Ltd stock price (2290.5 JPY) is 50% less than its Intrinsic Value (4 552.2 JPY).
Ono Pharmaceutical Co Ltd stock price (2290.5 JPY) is 59% less than its DCF Value (5 556.37 JPY). Open DCF Valuation
Ono Pharmaceutical Co Ltd stock price (2290.5 JPY) is 35% less than its Relative Value (3 548.03 JPY). Open Relative Valuation
Ono Pharmaceutical Co Ltd has upside potential of 23% compared to the average analyst price target.
Open Wall St Estimates
Ono Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
Ono Pharmaceutical Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 13% to 17%.
Ono Pharmaceutical Co Ltd's Revenue has grown by 16% over the past 12 months.
Ono Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 17%.
Ono Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 13% to 19%.
Ono Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 19%.
Ono Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 14%. The company is efficient at transforming stockholders' equity into net income.
Ono Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 15%. The company is efficient at using invested capital to generate operating income.
Ono Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Ono Pharmaceutical Co Ltd's Revenue has been growing by 18% per year for the last 3 years.
Ono Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Ono Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Ono Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Ono Pharmaceutical Co Ltd's short-term assets (354B JPY) exceed its short-term liabilties (90B JPY).
Ono Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.01.
Ono Pharmaceutical Co Ltd's long-term assets (892B JPY) exceed its long-term liabilties (107B JPY).
Ono Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (136B JPY) than debt (6B JPY).
Ono Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 9.26.
Ono Pharmaceutical Co Ltd earns more than enough operating income (164B JPY) to safely cover interest payments on its debt (96m JPY).
Valuation Backtest
Ono Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Ono Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ono Pharmaceutical Co Ltd
Balance Sheet Decomposition
Ono Pharmaceutical Co Ltd
| Current Assets | 354.3B |
| Cash & Short-Term Investments | 135.6B |
| Receivables | 150.5B |
| Other Current Assets | 68.2B |
| Non-Current Assets | 537.5B |
| Long-Term Investments | 335.9B |
| PP&E | 104.8B |
| Intangibles | 59B |
| Other Non-Current Assets | 37.8B |
| Current Liabilities | 89.7B |
| Accounts Payable | 53.1B |
| Other Current Liabilities | 36.6B |
| Non-Current Liabilities | 17.4B |
| Long-Term Debt | 6.3B |
| Other Non-Current Liabilities | 11B |
Earnings Waterfall
Ono Pharmaceutical Co Ltd
|
Revenue
|
498.1B
JPY
|
|
Cost of Revenue
|
-121.7B
JPY
|
|
Gross Profit
|
376.3B
JPY
|
|
Operating Expenses
|
-212.3B
JPY
|
|
Operating Income
|
164B
JPY
|
|
Other Expenses
|
-36.4B
JPY
|
|
Net Income
|
127.6B
JPY
|
Free Cash Flow Analysis
Ono Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Ono Pharmaceutical Co Ltd's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Ono Pharmaceutical Co Ltd's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ono Pharmaceutical Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Ono Pharmaceutical Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ono Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Ono Pharmaceutical Co Ltd
is 2 816.13 JPY
with a low forecast of 2 121 JPY and a high forecast of 5 428.5 JPY.
Shareholder Return
Price
Ono Pharmaceutical Co Ltd
| Average Annual Return | 11.89% |
| Standard Deviation of Annual Returns | 16.45% |
| Max Drawdown | -42% |
| Market Capitalization | 1.1T JPY |
| Shares Outstanding | 469 712 992 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Ono Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company is headquartered in Osaka, Osaka-Fu and currently employs 3,607 full-time employees. The firm operates in one business segment. The Pharmaceutical segment involves in the manufacture and sale of drugs for medical and general use. The firm also involves in the clinical development, introduction and derivation of pharmaceuticals.
Contact
IPO
Employees
Officers
The intrinsic value of one
Ono Pharmaceutical Co Ltd
stock under the Base Case scenario is
4 552.2
JPY.
Compared to the current market price of 2 290.5 JPY,
Ono Pharmaceutical Co Ltd
is
Undervalued by 50%.
You don't have any saved screeners yet
